BioSpace News Archive

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), today announced it has received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, for the Company’s potentially pivotal study of Berubicin.

Rubius Therapeutics, Inc. today announced that for the second year in a row the Boston Globe has named the Company among its annual Top Places to Work in Massachusetts.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces the successful completion of the first surgery in the U.S. utilizing Pixee Medical, an FDA-cleared augmented reality surgical application for assistance in total knee arthroplasties.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent application number 17/234,490, titled “Illumination for Photodynamic Therapy,” that covers an innovative, pain-reducing illumination protocol for photodynamic therapy (PDT).

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December 3 – 7 in Chicago, Illinois.

Discovery Life Sciences™, the biospecimen and biomarker specialists™, announced that it has acquired In Vitro ADMET Laboratories to add the world’s largest hepatocyte inventory and a world-renowned scientific leader to its growing company.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into an amendment to its previously announced transaction agreement with AiPharma Global extending the outside date by which the parties have to execute a definitive agreement from November 30, 2021 to December 16, 2021,

Amzell B.V. (Amzell), a specialist development pharmaceutical company, and Amring Pharmaceuticals Inc. announced today that they will be in attendance at the 2021 American Epilepsy Society (AES) Annual Meeting. The meeting will be held from Dec 3 to Dec 7, 2021, at McCormick Place West in Chicago, IL.

The ultrasonic electrosurgical devices market has been predicted to grow at a noticeable pace during the forecast period.